The July meeting delivered a mix of outcomes, but almost every approval came with conditions. From osteoporosis and Crohn’s disease to multiple cancers and rare disorders, PBAC required steep price reductions and risk-sharing arrangements for PBS listing. …
PBAC delivers recommendations dominated by price cuts and risk shares
August 25, 2025 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Cartherics and Catalent deepen partnership to accelerate next generation cell therapies
April 10, 2026 - - Australian Biotech -
Lower official co-payment but patients paying for more unsubsidised medicines
April 10, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 10 April
April 10, 2026 - - Podcast -
Is there any example of another review or inquiry taking this long?
April 10, 2026 - - Latest News -
Rewriting the rules of PBS negotiations to deliver a patient-first reset
April 10, 2026 - - Latest News -
A decade of readiness as AVITA medical expands burn response capability
April 9, 2026 - - Australian Biotech -
Moderna names Carolyn Tucek-Szabo to lead Australia and New Zealand operations
April 9, 2026 - - Latest News